Searched for
ALMIRALL
Glenmark bets on respiratory drug, licensing deals to improve businessGlenmark had gross debt of ₹3,765 crore as of June 30, 2022. The company over the years accumulated debt to fund its innovation-led R&D and...- Glenmark Q4 Results: Net dips 26% to Rs 173 crConsolidated revenues of the drug firm, however, rose to Rs 3,019 crore in the quarter under review as compared to Rs 2,860 crore in the ye...
- Stocks in the news: Vodafone Idea, Tata Steel, Sun Pharma, Adani Transmission & ZEELIndia Ratings and Research (Ind-Ra) said it has upgraded Tata Steel's long-term issuer rating to 'AA+' from 'AA'.
- Glenmark looks to license out second drug assetGlenmark chairman and managing director Glenn Saldanha said one of the corporate objectives of the Mumbai-headquartered company is to do at...
- Stocks in the news: ITC, Vedanta, SBI, Emami, HDFC and NatcoMulti-business conglomerate ITC has not given any concrete plan for demerger and listing of businesses to unlock value at its analyst meet.
- Glenmark's subsidiary Ichnos Sciences enters pact with Almirall for novel drug to treat autoimmune diseasesUnder the agreement, Almirall is granted global rights to develop and commercialize this monoclonal antibody for autoimmune diseases. Ichno...
- UK pharma group Vectura agrees $1.4 billion takeover by CarlyleVectura's Chairman Bruno Angelici said the company had made strong progress since embarking on a strategy in 2019 to become a leading inhal...
- Sun Pharma jumps 2% as partner gets drug nodThe stock rose 2.28 per cent to hit a high of Rs 657 on the BSE.
- MCX, Sun Pharma, PNB Housing and Strides Pharma among stocks in the newsHere's a look at the top stocks that may hog the limelight in today's session.
- Sun marches ahead with its specialty pipeline, announces European approval for TildraIn the last two months Sun Pharma has received approval for four drugs from its pipeline after a dry spell of nearly 2 years.
- Decoding the impact of Ilumya, Sun Pharma's first biologic drug approved by the US FDALast year Sun Pharma signed another deal with South Korea's Samsung Biologics to get the drug manufactured on approval.
- Tildra approval to give sentimental push to Sun PharmaThe drug which will be sold under the brand name Ilumya is expected to treat adults for moderate to severe plaque psoriasis, an autoimmune ...
- Sun Pharmaceutical signs agreement with Samsung BioLogics for psoriasis drugThe novel drug known as Tildrakizumab is currently under review by the US FDA and the European Medicines Agency (EMA). The value of the con...
- Almirall seeks nod for tildrakizumab in Europe: Sun PharmaThe filing includes efficacy and safety data from the pivotal Phase III clinical trials that included over 1,800 patients across more than ...
- Operational performance, Ranbaxy integration make Sun Pharma stock analysts' top pickSun Pharma is also striving to transform itself from a generics player to a speciality player with a focus on therapies like dermatology, o...
- Sun Pharma announces details of psoriasis drug trialsTildrakizumab is a monoclonal antibody designed to control the pathogenic cells responsible for the inflammatory process of psoriasis with ...
- Sun Pharmaceuticals among bidders for Bayer’s dermatology brandsPrivate equity players KKR, Nordic Capital, Bain Capital, Blackstone and Cinven may also be looking at buying the same assets.
- Sun Pharma rises after licensing deal with AlmirallAt 11:01 am, shares of the company were trading at Rs 817.80 per share, up 1.24 per cent from its previous close on the Bombay Stock Exchan...
- Sun Pharma signs licening pact with spanish firm Almirall for psoriasis drugIn return, the Indian company will receive an initial upfront payment of $50 million and be eligible for development and regulatory milesto...
- 3M sells pharma business to 4 companies for $2.1bn3M, which makes Scotch tape, stethoscopes and electronic road signs, agreed to sell its pharmaceutical division for $2.1bn to focus on prod...
Load More
